Core¹ operating profit$596m
Profit to shareholders$188m
Core profit to shareholders$406m
Basic earnings per share84c
Core basic earnings per share181c
Dividend per share56c
- Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 of the Group consolidated financial statements
- EBTIDA is earnings before interest, tax, depreciation, amortisation, assets write-down, impairment charges/reversals and unwinding of acquisition related inventory step-up. Core EBITDA is adjusted for exceptional items
Preliminary Results 2022
Key Highlights from Said Darwazah, Executive Chairman and Chief Executive Officer
Key highlights from Khalid Nabilsi, Chief Financial Officer
Key highlights from Riad Mishlawi, President, Injectables
Key highlights from Mazen Darwazah, Executive Vice Chairman and President MENA
Key highlights from Brian Hoffmann, President Generics
Four reasons to invest in Hikma
We have a strong business model with significant opportunities to further enhance our portfolio to drive growth and deliver value for shareholders.
Find out how our business model, strategy and established capabilities support our clear investment proposition
3 August 2023
2023 Interim Results Announcement
2 November 2023
November Trading Update
News feed from the London Stock Exchange's Regulatory News Service.
Download our Corporate Factsheet
Information on the high standards of governance we’re committed to, our governance structure, Board, key committees, and remuneration policy.